J Ghaffari, M Gharegozlou, E Mohammadzadeh, Z Nazari,
Volume 17, Issue 61 (12-2007)
Abstract
Background and Purpose: Intravenous immunoglobulin is used for primary immunodeficiency disorders. There have been some reports that intravenous immunoglobulin causes side effects. The aim of this study was to investigate intravenous immunoglobulin side effects in immunodeficiency patients.
Materials and Methods: The study utilized the data of 29 primary immunodeficiency patients that were referred to allergy and immunology department in Medical Children Center in Tehran. 29 patients having completed record data files in the hospital, were the subjects of this study.
Results: Of 29 immune deficiency patients (aged 15 months to 55 years), they were 19 Males (65/51%) and 10(34/48%) Females. Prevalence of disorders include common variable immunodeficiency 16(55/17%), Bruton disease 8(27/58%), hyper IgM 4 (13/79%) and severe combind immunodeficiency 1 (3/44%). Based on the recorded data, the duration of infusion has been 5 months to 15 years. 15 patients had reported side effects (51/72%). 34 infusions from the total of 1,626 infusions accompanied with side effects (2/09%). Most side effects were occurred during 30 minutes onset of infusion and most were caused by rapid infusion. Most side effects were mild reactions (fever, chills and …).
Conclusion: Intravenous immunoglobulin is a rather safe drug with mild side effects. With an appropriate technique and proper infusion, these side effects can be reduced.
Fatemeh Niksolat, Hadi Majidi, Ghasem Rahmatpour Rokni, Saeed Dashti Dargahloo, Mohammad Tabarestani, Sarah Sadr,
Volume 28, Issue 160 (5-2018)
Abstract
Scleromyxedema (SM), a rare progressive cutaneous mucinosis with a systemic involvement, presents with progressive dermal mucin depositions, causing skin thickening. In addition to the skin involvement and paraproteinemia, patients with SM also have other complications. The systems which are commonly involved include the gastrointestinal, musculoskeletal, pulmonary, cardiovascular, renal, and central nervous systems. Scleromyxedema is difficult to treat. We present a patient with severe Scleromyxedema with cutaneous, gastrointestinal, musculoskeletal and renal manifestations. Following failed therapeutic attempts, she responded to treatment with intravenous gammaglobulin (IVIG), prednisolone, and azathioprine. As a result of treatment with IVIG, the patient showed dramatic improvement in her clinical symptoms and remained in remission throughout the course of combination IVIG infusions and prednisolone. We concluded that an IVIG-prednisolone combination may be an effective novel treatment of Scleromyxedema.
